Nano-PROTACs: state of the art and perspectives

Jie Zhong, Ruiqi Zhao, Yuji Wang, Yu-xiong Su and Xinmiao Lan

Nanoscale, 2024, 16, 4378
DOI: 10.1039/D3NR06059D

In vitro and in vivo ADME of heterobifunctional degraders: a tailored approach to optimize DMPK properties of PROTACs©

Christine Katharina Maurer, Zhizhou Fang, Christina Schindler, Gianna Pohl, Fouzia Machrouhi-Porcher, Marc Lecomte, Carl Petersson and Heide Marika Duevel

RSC Med. Chem., 2025, 16, 1746
DOI: 10.1039/D4MD00854E

Technical, preclinical, and clinical developments of Fc-glycan-specific antibody–drug conjugates

Qiang Yang and Yunpeng Liu

RSC Med. Chem., 2025, 16, 50
DOI: 10.1039/D4MD00637B

Chemistries of bifunctional PROTAC degraders

Chaoguo Cao, Ming He, Liguo Wang, Yuna He and Yu Rao

Chem. Soc. Rev., 2022, 51, 7066
DOI: 10.1039/D2CS00220E

Innovative, combinatorial and high-throughput approaches to degrader synthesis

Rebecca Stevens, James D. F. Thompson, Julie C. L. Fournier, Glenn A. Burley, David J. Battersby and Afjal H. Miah

Chem. Soc. Rev., 2024, 53, 4838
DOI: 10.1039/D3CS01127E

Chemically induced degradation of epigenetic targets

Md Kabir, Xufen Yu, H. Ümit Kaniskan and Jian Jin

Chem. Soc. Rev., 2023, 52, 4313
DOI: 10.1039/D3CS00100H

PROTACs bearing piperazine-containing linkers: what effect on their protonation state?

Jenny Desantis, Andrea Mammoli, Michela Eleuteri, Alice Coletti, Federico Croci, Antonio Macchiarulo and Laura Goracci

RSC Adv., 2022, 12, 21968
DOI: 10.1039/D2RA03761K

Bispecific antibody drug conjugates: Making 1+1>2

Yilin Gu, Zhijia Wang and Yuxi Wang

Acta Pharmaceutica Sinica B, 2024, 14, 1965
DOI: 10.1016/j.apsb.2024.01.009

PROTAC 2.0: Expanding the frontiers of targeted protein degradation

Marie Cornu, Thomas Lemaitre, Charline Kieffer and Anne Sophie Voisin-Chiret

Drug Discovery Today, 2025, 30, 104376
DOI: 10.1016/j.drudis.2025.104376

New techniques and strategies in drug discovery (2020–2024 update)

Qijie Gong, Jian Song, Yihui Song, Kai Tang, Panpan Yang, Xiao Wang, Min Zhao, Liang Ouyang, Li Rao, Bin Yu, Peng Zhan, Saiyang Zhang and Xiaojin Zhang

Chinese Chemical Letters, 2025, 36, 110456
DOI: 10.1016/j.cclet.2024.110456

Precision targeting in oncology: The future of conjugated drugs

Jia-He Li, Lei Liu and Xi-He Zhao

Biomedicine & Pharmacotherapy, 2024, 177, 117106
DOI: 10.1016/j.biopha.2024.117106

An NTCP-mediated liver-targeting chimeras (NTLiverTac) design strategy and its application to hepatoblastoma models

Jing Liang, Weihong Luo, Wen Xu, Siting Song, Yutong Li, Yang Liu, Hua Li and Lixia Chen

Bioorganic Chemistry, 2025, 162, 108622
DOI: 10.1016/j.bioorg.2025.108622

Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations

Richa Vartak, Bhavesh Deore, Carlos A. Sanhueza and Ketan Patel

International Journal of Biological Macromolecules, 2023, 252, 126413
DOI: 10.1016/j.ijbiomac.2023.126413

Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy

Davide Izzo, Liliana Ascione, Lorenzo Guidi, Renato Maria Marsicano, Chrysanthi Koukoutzeli, Dario Trapani and Giuseppe Curigliano

Ther Adv Med Oncol, 2025, 17
DOI: 10.1177/17588359241309461

Targeting ferroptosis: Paving new roads for drug design and discovery

Yilin Gu, Yizhe Li, Jiaxing Wang, Lele Zhang, Jifa Zhang and Yuxi Wang

European Journal of Medicinal Chemistry, 2023, 247, 115015
DOI: 10.1016/j.ejmech.2022.115015

Pharmaceutical innovation and advanced biotechnology in the biotech-pharmaceutical industry for antibody–drug conjugate development

Qi Ma, Puro Durga, Frederick X.C. Wang, Hang-Ping Yao and Ming-Hai Wang

Drug Discovery Today, 2024, 29, 104057
DOI: 10.1016/j.drudis.2024.104057

Payload diversification: a key step in the development of antibody–drug conjugates

Louise Conilh, Lenka Sadilkova, Warren Viricel and Charles Dumontet

J Hematol Oncol, 2023, 16
DOI: 10.1186/s13045-022-01397-y

CD36-mediated endocytosis of proteolysis-targeting chimeras

Zhengyu Wang, Bo-Syong Pan, Rajesh Kumar Manne, Jungang Chen, Dongwen Lv, Minmin Wang, Phuc Tran, Tsigereda Weldemichael, Wei Yan, Hongfei Zhou, Gloria M. Martinez, Jingwei Shao, Che-Chia Hsu, Robert Hromas, Daohong Zhou, Zhiqiang Qin, Hui-Kuan Lin and Hong-Yu Li

Cell, 2025, 188, 3219
DOI: 10.1016/j.cell.2025.03.036

Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads

Meiyang Xi, Jingjing Zhu, Fengxia Zhang, Hualiang Shen, Jianhui Chen, Ziyan Xiao, Yanping Huangfu, Chunlei Wu, Haopeng Sun and Gang Xia

European Journal of Medicinal Chemistry, 2024, 276, 116709
DOI: 10.1016/j.ejmech.2024.116709

The New Frontier: Merging Molecular Glue Degrader and Antibody–Drug Conjugate Modalities To Overcome Strategic Challenges

Yam B. Poudel, Ruchita R. Thakore and Eugene P. Chekler

J. Med. Chem., 2024, 67, 15996
DOI: 10.1021/acs.jmedchem.4c01289

Sirtuin 3 as a promising target in disease therapy: Model action and drug discovery

Dongmin Yu

European Journal of Medicinal Chemistry, 2025, 297, 117929
DOI: 10.1016/j.ejmech.2025.117929

Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies

Deping Li, Xiaopeng Peng, Zhihao Hu, Shuqing Li, Jianjun Chen and Wanyi Pan

European Journal of Medicinal Chemistry, 2024, 264, 115982
DOI: 10.1016/j.ejmech.2023.115982

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

Chao Wang, Yujing Zhang, Wujun Chen, Yudong Wu and Dongming Xing

Mol Cancer, 2024, 23
DOI: 10.1186/s12943-024-02024-9

Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs

Donglu Zhang, Bin Ma, Peter S. Dragovich, Li Ma, Shu Chen, Eugene C. Chen, Xiaofen Ye, Joyce Liu, Jennifer Pizzano, Elizabeth Bortolon, Emily Chan, Xing Zhang, Yi-Chen Chen, Elizabeth S. Levy, Robert L. Yauch, S. Cyrus Khojasteh and Cornelis E. C. A. Hop

Commun Med, 2024, 4
DOI: 10.1038/s43856-024-00505-y

Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins

Qun Zhou

Molecules, 2023, 28, 917
DOI: 10.3390/molecules28030917

Antibody–drug conjugates come of age in oncology

Charles Dumontet, Janice M. Reichert, Peter D. Senter, John M. Lambert and Alain Beck

Nat Rev Drug Discov, 2023, 22, 641
DOI: 10.1038/s41573-023-00709-2

Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma

Ali Al Sbihi, Maryam Alasfour and Georgios Pongas

Cancers, 2024, 16, 827
DOI: 10.3390/cancers16040827

Development of Ligands and Degraders Targeting MAGE-A3

Ke Li, Mackenzie W. Krone, Arseniy Butrin, Michael J. Bond, Brian M. Linhares and Craig M. Crews

J. Am. Chem. Soc., 2024, 146, 24884
DOI: 10.1021/jacs.4c05393

Application of Artificial Intelligence and Computational Biology in Protein Drug Development

Jiacheng Jiang, Wen Li, Weiran Huang, Xinyi Lou, Xinyi Shi, Chen Guo, Xueni Yu, Nafisa Tursumamat, Guodong Wu, Qiannan Liu, Yuting Huang, Buyong Ma and Bo Zhao

Pharmaceutical Fronts, 2025, 07, e22
DOI: 10.1055/a-2520-3833

Welding PROxAb Shuttles: A Modular Approach for Generating Bispecific Antibodies via Site-Specific Protein–Protein Conjugation

Tanja Lehmann, Hendrik Schneider, Jason Tonillo, Jennifer Schanz, Daniel Schwarz, Christian Schröter, Sebastian Jäger, Harald Kolmar, Stefan Hecht, Jan Anderl, Nicolas Rasche, Marcel Rieker and Stephan Dickgiesser

Bioconjugate Chem., 2024, 35, 780
DOI: 10.1021/acs.bioconjchem.4c00124

Self‐Assembled Peptide‐Derived Proteolysis‐Targeting Chimera (PROTAC) Nanoparticles for Tumor‐Targeted and Durable PD‐L1 Degradation in Cancer Immunotherapy

Yujeong Moon, Hanhee Cho, Jinseong Kim, Sukyung Song, Jung Yeon Park, Jin Young Min, Eun Hee Han, Yongju Kim, Joon‐Kyung Seong, Man Kyu Shim and Kwangmeyung Kim

Angew Chem Int Ed, 2025, 64
DOI: 10.1002/anie.202414146

Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy

Devesh Aggarwal, Jie Yang, Md. Abdus Salam, Sagnik Sengupta, Md. Yusuf Al-Amin, Saad Mustafa, Mohammad Aasif Khan, Xun Huang and Jogendra Singh Pawar

Front. Immunol., 2023, 14
DOI: 10.3389/fimmu.2023.1203073

Targeted Strategies for Degradation of Key Transmembrane Proteins in Cancer

Vehary Sakanyan, Nina Iradyan and Rodolphe Alves de Sousa

BioTech, 2023, 12, 57
DOI: 10.3390/biotech12030057

Opportunities and Challenges in Antibody–Drug Conjugates for Cancer Therapy: A New Era for Cancer Treatment

Idil Buyukgolcigezli, Ates Kutay Tenekeci and Ibrahim Halil Sahin

Cancers, 2025, 17, 958
DOI: 10.3390/cancers17060958

Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions

Renata Pacholczak-Madej, Małgorzata Meluch and Mirosława Püsküllüoğlu

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025, 1880, 189369
DOI: 10.1016/j.bbcan.2025.189369

Prodrug Approach as a Strategy to Enhance Drug Permeability

Mateus Mello de Souza, Ana Luísa Rodriguez Gini, Jhonnathan Alves Moura, Cauê Benito Scarim, Chung Man Chin and Jean Leandro dos Santos

Pharmaceuticals, 2025, 18, 297
DOI: 10.3390/ph18030297

Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer

Jia‐Yi Lin, Hai‐Jun Liu, Ye Wu, Jin‐Mei Jin, Yu‐Dong Zhou, Hong Zhang, Dale G. Nagle, Hong‐Zhuan Chen, Wei‐Dong Zhang and Xin Luan

Small, 2023, 19
DOI: 10.1002/smll.202207778

Self‐Assembled Peptide‐Derived Proteolysis‐Targeting Chimera (PROTAC) Nanoparticles for Tumor‐Targeted and Durable PD‐L1 Degradation in Cancer Immunotherapy

Yujeong Moon, Hanhee Cho, Jinseong Kim, Sukyung Song, Jung Yeon Park, Jin Young Min, Eun Hee Han, Yongju Kim, Joon‐Kyung Seong, Man Kyu Shim and Kwangmeyung Kim

Angewandte Chemie, 2025, 137
DOI: 10.1002/ange.202414146

Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology

Irene Sevilla-Carrillo, Eloína García-Tercero, Carlos Alonso-Moreno and Carmen Moya-Lopez

ACAMC, 2025, 25, 993
DOI: 10.2174/0118715206348204241128063329

Autophagy receptor-inspired chimeras: a novel approach to facilitate the removal of protein aggregates and organelle by autophagy degradation

Liwen Wang, Huimei Liu and Lanfang Li

J. Zhejiang Univ. Sci. B, 2024, 25, 1115
DOI: 10.1631/jzus.B2300853

How Should we Teach Medicinal Chemistry in Higher Education to Prepare Students for a Future Career as Medicinal Chemists and Drug Designers? – A Teacher's Perspective

Philipp Klahn

ChemMedChem, 2025, 20
DOI: 10.1002/cmdc.202400791

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance

Huanjie Zhu, Jin Wang, Qingqing Zhang, Xiaoyan Pan and Jie Zhang

Pharmacology & Therapeutics, 2023, 244, 108371
DOI: 10.1016/j.pharmthera.2023.108371

Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis

Mirosława Püsküllüoğlu, Agnieszka Rudzińska and Renata Pacholczak-Madej

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023, 1878, 188991
DOI: 10.1016/j.bbcan.2023.188991

Development of therapeutic antibodies for the treatment of diseases

Zeng Wang, Guoqing Wang, Huaqing Lu, Hongjian Li, Mei Tang and Aiping Tong

Mol Biomed, 2022, 3
DOI: 10.1186/s43556-022-00100-4

Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions

Tinglin Yang, Wenhui Li, Tao Huang and Jun Zhou

IJMS, 2023, 24, 11903
DOI: 10.3390/ijms241511903

Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research

Xiang Li, Qian Liu, Xin Xie, Cheng Peng, Qiwen Pang, Bo Liu and Bo Han

J. Med. Chem., 2023, 66, 1700
DOI: 10.1021/acs.jmedchem.2c01712

Antibody–drug conjugates: Recent advances in payloads

Zhijia Wang, Hanxuan Li, Lantu Gou, Wei Li and Yuxi Wang

Acta Pharmaceutica Sinica B, 2023, 13, 4025
DOI: 10.1016/j.apsb.2023.06.015

Discovery of High-Affinity SMARCA2/4 Bromodomain Ligands and Development of Potent and Exceptionally Selective SMARCA2 PROTAC Degraders

Lingying Leng, Wenbin Tu, Lin Yang, Liyue Huang, Mi Wang, Jennifer L. Meagher, Krishnapriya Chinnaswamy, Srinivasa Rao Allu, Rohan Kalyan Rej, Jelena Tošović, Lalgudi Harikrishnan, Zhenwu Li, Zhihua Sui, Jeanne A. Stuckey and Shaomeng Wang

J. Med. Chem., 2025, 68, 1113
DOI: 10.1021/acs.jmedchem.4c01903

Targeting the Undruggable: Recent Progress in PROTAC-Induced Transcription Factor Degradation

Hyein Jung and Yeongju Lee

Cancers, 2025, 17, 1871
DOI: 10.3390/cancers17111871

Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy

Qi He, Liming Zhou, Daxin Yu, Ren Zhu, Yue Chen, Mingbo Song, Xintong Liu, Yixian Liao, Tong Ding, Wenpei Fan and Wenying Yu

J. Med. Chem., 2023, 66, 10458
DOI: 10.1021/acs.jmedchem.3c00587

Liver-targeting chimeras as a potential modality for the treatment of liver diseases

Chuanjie Chen, Yongzhang Pan, Xiaoyu Yang, Huiqin Li, Xinhui Cai, Shengyuan He, Qiong Wang, Yiwen Yang, Runzi Zheng, Huiwen Li, Shengjie Yuan, Xin Dong, Priyadarshani Nadeeshika Samarawickrama, Meiting Zi, Yonghan He and Xuan Zhang

Journal of Controlled Release, 2024, 374, 627
DOI: 10.1016/j.jconrel.2024.08.044

Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement

Mingxia Jiang, Qiao Li and Binghe Xu

Drug Resistance Updates, 2024, 75, 101086
DOI: 10.1016/j.drup.2024.101086

Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers

Georgina B Armstrong, Harriet Graham, Anthony Cheung, Hanieh Montaseri, Glenn A Burley, Sophia N Karagiannis and Zahra Rattray

Advanced Drug Delivery Reviews, 2025, 224, 115648
DOI: 10.1016/j.addr.2025.115648

Non-clinical safety evaluations of next-generation therapeutic antibodies

Kaito Nihira

Folia Pharmacol. Jpn., 2022, 157, 458
DOI: 10.1254/fpj.22049

Delivering on the promise of protein degraders

Matthew N. O’Brien Laramy, Suman Luthra, Matthew F. Brown and Derek W. Bartlett

Nat Rev Drug Discov, 2023, 22, 410
DOI: 10.1038/s41573-023-00652-2

Protein Ligases: Nature’s Gift for Protein/Peptide Synthesis

Yvonne Ritsema, Huapeng Li and Qingfei Zheng

BioChem, 2025, 5, 11
DOI: 10.3390/biochem5020011

Fifty years of monoclonals: the past, present and future of antibody therapeutics

Andrew C. Chan, Greg D. Martyn and Paul J. Carter

Nat Rev Immunol, 2025
DOI: 10.1038/s41577-025-01207-9

CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications

Riya Thapa, Asif Ahmad Bhat, Gaurav Gupta, S. Renuka Jyothi, Irwanjot Kaur, Sachin Kumar, Naveen Sharma, G. V. Siva Prasad, Atreyi Pramanik and Haider Ali

Chem Biol Drug Des, 2024, 104
DOI: 10.1111/cbdd.70009

Design and Application of Cereblon-Recruiting Prodegraders

Davis H. Chase, Alicia Stein, Daniel E. Grinshpun, Mackenzie W. Krone and Craig M. Crews

J. Am. Chem. Soc., 2025, 147, 24527
DOI: 10.1021/jacs.5c05036

Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes

Janarthanan Venkatesan, Dhanashree Murugan, Kalaiarasu Lakshminarayanan, Alexis R. Smith, Harashkumar Vasanthakumari Thirumalaiswamy, Hariprasath Kandhasamy, Boutheina Zender, Guangrong Zheng and Loganathan Rangasamy

Pharmacology & Therapeutics, 2024, 263, 108725
DOI: 10.1016/j.pharmthera.2024.108725

High‐Throughput Miniaturized Synthesis of PROTAC‐Like Molecules

Ye Tian, Maximilian Seifermann, Liana Bauer, Charlotte Luchena, Janne J. Wiedmann, Stefan Schmidt, Alexander Geisel, Sergii Afonin, Julius Höpfner, Marius Brehm, Xinyong Liu, Carsten Hopf, Anna A. Popova and Pavel A. Levkin

Small, 2024, 20
DOI: 10.1002/smll.202307215

A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)

Aina Urbina, Alex J. Hallatt, Jack Robertson and Alessio Ciulli

Expert Opinion on Therapeutic Patents, 2025, 35, 197
DOI: 10.1080/13543776.2024.2446232

Disintegrate (DIN) Theory Enabling Precision Engineering of Proteins

Preeti Chauhan, Ragendu V., Mohan Kumar, Rajib Molla, Unnikrishnan V. B. and Vishal Rai

ACS Cent. Sci., 2023, 9, 137
DOI: 10.1021/acscentsci.2c01455

ELiAH: the atlas of E3 ligases in human tissues for targeted protein degradation with reduced off-target effect

Hyojung Paik, Chunryong Oh, Sajid Hussain, Sangjae Seo, Soon Woo Park, Tae Lyun Ko and Ari Lee

Database, 2024, 2024
DOI: 10.1093/database/baae111

Protein degraders enter the clinic — a new approach to cancer therapy

Deborah Chirnomas, Keith R. Hornberger and Craig M. Crews

Nat Rev Clin Oncol, 2023, 20, 265
DOI: 10.1038/s41571-023-00736-3

Aptamer-Based Targeted Protein Degradation

Yuan Liu, Xu Qian, Chunyan Ran, Longjie Li, Ting Fu, Dan Su, Sitao Xie and Weihong Tan

ACS Nano, 2023, 17, 6150
DOI: 10.1021/acsnano.2c10379

Antibody-drug conjugates in cancer therapy: applications and future advances

Rou Long, Hanrong Zuo, Guiyang Tang, Chaohui Zhang, Xinru Yue, Jinsai Yang, Xinyu Luo, Yuqi Deng, Jieya Qiu, Jiale Li and Jianhong Zuo

Front. Immunol., 2025, 16
DOI: 10.3389/fimmu.2025.1516419

Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines

Karina Chan, Preethi Soundarya Sathyamurthi, Markus A. Queisser, Michael Mullin, Harry Shrives, Diane M. Coe and Glenn A. Burley

Bioconjugate Chem., 2023, 34, 2049
DOI: 10.1021/acs.bioconjchem.3c00366

Reinventing chemotherapy

Bruce A Chabner, Jacob Gehri and Beatrix B Thompson

The Oncologist, 2025, 30
DOI: 10.1093/oncolo/oyae331

The Emergence of Oligonucleotide Building Blocks in the Multispecific Proximity-Inducing Drug Toolbox of Destruction

Kevin Xiao Tong Zhou and Katherine E. Bujold

ACS Chem. Biol., 2025, 20, 3
DOI: 10.1021/acschembio.4c00311

Emerging Proteolysis Targeting Antibodies (PROTABs) for Application in Cancer Therapy

Robert B. Kargbo

ACS Med. Chem. Lett., 2022, 13, 1833
DOI: 10.1021/acsmedchemlett.2c00458

In Vivo Self‐Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy

Shaowen Xie, Jingjie Zhu, Yihan Peng, Fangyi Zhan, Feiyan Zhan, Chen He, Dazhi Feng, Jia Xie, Jingyu Liu, Huajian Zhu, Hong Yao, Jinyi Xu, Zhigui Su and Shengtao Xu

Angew Chem Int Ed, 2025, 64
DOI: 10.1002/anie.202421713

Antibody–drug conjugates: prospects for the next generation

Meriem Grairi and Marc Le Borgne

Drug Discovery Today, 2024, 29, 104241
DOI: 10.1016/j.drudis.2024.104241

Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier

Toshihiko Tashima

Antibodies, 2023, 12, 43
DOI: 10.3390/antib12030043

Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics

Yupiao Feng, Xinting Hu and Xin Wang

Biomark Res, 2024, 12
DOI: 10.1186/s40364-024-00638-1

Biotransformation research advances – 2022 year in review

S. Cyrus Khojasteh, Upendra A. Argikar, Lionel Cheruzel, Sungjoon Cho, Rachel D. Crouch, Deepika Dhaware, Carley J. S. Heck, Kevin M. Johnson, Amit S. Kalgutkar, Lloyd King, Joyce Liu, Bin Ma, Hlaing Maw, Grover P. Miller, Herana Kamal Seneviratne, Ryan H. Takahashi, Shuai Wang, Cong Wei and Klarissa D. Jackson

Drug Metabolism Reviews, 2023, 55, 301
DOI: 10.1080/03602532.2023.2262161

Targeted degradation of LRG1 to attenuate renal fibrosis

Linyao Fan, Yingqiu Qi, Xi Yang, Yarui Xu, Yana Zhang, Longdi Wang, Anying Zhu, Lirong Zhang, Jian Song, Shengnan Du, Guangjun Nie and Huan Min

Asian Journal of Pharmaceutical Sciences, 2024, 19, 100941
DOI: 10.1016/j.ajps.2024.100941

Amphiphilic Affibody-PROTAC conjugate Self-Assembled nanoagents for targeted cancer therapy

Wenhui Gao, Xuelin Xia, Xiaoyuan Yang, Qingrong Li, Xiaoxia Xia, Wei Huang and Deyue Yan

Chemical Engineering Journal, 2024, 495, 153437
DOI: 10.1016/j.cej.2024.153437

In Vivo Self‐Assembly of PROTACs by Bioorthogonal Chemistry for Precision Cancer Therapy

Shaowen Xie, Jingjie Zhu, Yihan Peng, Fangyi Zhan, Feiyan Zhan, Chen He, Dazhi Feng, Jia Xie, Jingyu Liu, Huajian Zhu, Hong Yao, Jinyi Xu, Zhigui Su and Shengtao Xu

Angewandte Chemie, 2025, 137
DOI: 10.1002/ange.202421713

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs

Rui Yao, Tianli Luo and Ming Wang

ChemBioChem, 2023, 24
DOI: 10.1002/cbic.202300413

Targeting the undruggables—the power of protein degraders

Chao Zhang, Yongbo Liu, Guangchen Li, Zhouli Yang, Chi Han, Xiuyun Sun, Chunquan Sheng, Ke Ding and Yu Rao

Science Bulletin, 2024, 69, 1776
DOI: 10.1016/j.scib.2024.03.056

Targeted protein degradation for cancer therapy

Matthias Hinterndorfer, Valentina A. Spiteri, Alessio Ciulli and Georg E. Winter

Nat Rev Cancer, 2025, 25, 493
DOI: 10.1038/s41568-025-00817-8

A comprehensive review of BET-targeting PROTACs for cancer therapy

Xiao-Li Zhou, Fang Zhao, Yong-Tao Xu, Yuan-Yuan Guan, Tong Yu, Yi-Zhe Zhang, Ying-Chao Duan and Yuan Zhao

Bioorganic & Medicinal Chemistry, 2022, 73, 117033
DOI: 10.1016/j.bmc.2022.117033

Next steps for targeted protein degradation

Mackenzie W. Krone and Craig M. Crews

Cell Chemical Biology, 2025, 32, 219
DOI: 10.1016/j.chembiol.2024.10.004

A Review of Protein- and Peptide-Based Chemical Conjugates: Past, Present, and Future

Emily Holz, Martine Darwish, Devin B. Tesar and Whitney Shatz-Binder

Pharmaceutics, 2023, 15, 600
DOI: 10.3390/pharmaceutics15020600

CNS delivery of targeted protein degraders

Prashant Agarwal, Darren L. Reid and Mansoor Amiji

Journal of Controlled Release, 2024, 372, 661
DOI: 10.1016/j.jconrel.2024.06.057

What influences the activity of Degrader−Antibody conjugates (DACs)

Yaolin Guo, Xiaoxue Li, Yang Xie and Yuxi Wang

European Journal of Medicinal Chemistry, 2024, 268, 116216
DOI: 10.1016/j.ejmech.2024.116216

Degrader–Antibody Conjugates: Emerging New Modality

Ki Bum Hong and Hongchan An

J. Med. Chem., 2023, 66, 140
DOI: 10.1021/acs.jmedchem.2c01791

The rise of degrader drugs

Mingxing Teng and Nathanael S. Gray

Cell Chemical Biology, 2023, 30, 864
DOI: 10.1016/j.chembiol.2023.06.020

Expanding the horizons of targeted protein degradation: A non-small molecule perspective

Xiaowei Huang, Fengbo Wu, Jing Ye, Lian Wang, Xiaoyun Wang, Xiang Li and Gu He

Acta Pharmaceutica Sinica B, 2024, 14, 2402
DOI: 10.1016/j.apsb.2024.01.010

PROTAC Technology as a New Tool for Modern Pharmacotherapy

Natalia Kubryń, Łukasz Fijałkowski, Jacek Nowaczyk, Amer Jamil and Alicja Nowaczyk

Molecules, 2025, 30, 2123
DOI: 10.3390/molecules30102123